Tazobactum%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520piperacillin

# Piperacillin-Tazobactam ## Overview Piperacillin-tazobactam is a combination antibiotic consisting of piperacillin, a broad-spectrum penicillinase-susceptible penicillin, and tazobactam, a beta-lactamase inhibitor. It is active against many Gram-positive, Gram-negative, and anaerobic bacteria. ## Primary Indications * Complicated intra-abdominal infections * Complicated skin and skin-structure infections * Community-acquired pneumonia * Nosocomial pneumonia * Empirical treatment of febrile neutropenia (in combination with an aminoglycoside) * Other serious bacterial infections due to piperacillin-susceptible organisms. ## Adult Dosing Common adult dosing is 3.375 g (3 g piperacillin/0.375 g tazobactam) or 4.5 g (4 g piperacillin/0.5 g tazobactam) intravenously every 6 or 8 hours. * **Complicated Intra-abdominal Infections:** 3.375 g every 6 hours or 4.5 g every 8 hours for 5-14 days. * **Complicated Skin and Skin-Structure Infections:** 3.375 g every 6 hours or 4.5 g every 8 hours for 7-10 days. * **Community-Acquired Pneumonia:** 3.375 g every 6 hours for at least 7 days. * **Nosocomial Pneumonia:** 3.375 g every 6 hours or 4.5 g every 8 hours. Dosing may be increased to 4.5 g every 6 hours for severe infections. Treatment duration is typically 7-14 days. * **Febrile Neutropenia (Empirical):** Often given as 4.5 g every 6 hours, in combination with an aminoglycoside. Duration depends on resolution of neutropenia and clinical response. The frequency of administration (every 6 or 8 hours) is often guided by local protocols and the severity of infection. ## Pediatric Dosing **Children 2 months of age and older:** Dosing is based on piperacillin component. * **2 months to < 2 years:** Doses can range from 80 mg piperacillin/10 mg tazobactam/kg/day to 160 mg piperacillin/20 mg tazobactam/kg/day, administered every 6 or 8 hours. * **≥ 2 years:** Doses can range from 50 mg piperacillin/6.25 mg tazobactam/kg/day to 100 mg piperacillin/12.5 mg tazobactam/kg/day, administered every 6 or 8 hours. **Maximum pediatric doses:** Generally do not exceed the adult maximum dose of 4.5 g every 6 hours. ## Dose Adjustments **Renal Impairment:** * CrCl ≥ 40 mL/min: No dose adjustment needed. * CrCl 20-39 mL/min: 2.25 g (2 g piperacillin/0.25 g tazobactam) or 3.375 g (3 g piperacillin/0.375 g tazobactam) every 8 hours. * CrCl < 20 mL/min: 2.25 g every 8 hours. * **Hemodialysis:** 2.25 g every 8 hours, plus an additional 0.75 g dose after each dialysis session. **Hepatic Impairment:** No specific dose adjustments are routinely recommended, but caution is advised. ## Contraindications * Hypersensitivity to piperacillin, tazobactam, other penicillinase-resistant penicillins, or any component of the formulation. * History of severe immediate allergic reaction to a beta-lactam antibiotic. ## Adverse Effects * **Common:** Diarrhea, rash, nausea, vomiting, headache, insomnia, constipation, abdominal pain, thrombocytopenia, increased liver enzymes (AST, ALT). * **Serious:** Anaphylaxis, Clostridioides difficile-associated diarrhea, seizure (rare, particularly with high doses or renal impairment), interstitial nephritis, hemolytic anemia, Stevens-Johnson syndrome/toxic epidermal necrolysis. ## Key Drug Interactions * **Probenecid:** May increase and prolong piperacillin-tazobactam serum concentrations. * **Aminoglycosides:** Can inactivate each other when mixed in the same IV solution. May have synergistic or antagonistic effects depending on the pathogens. In combination therapy, administer separately. * **Neuromuscular blocking agents:** Piperacillin may prolong the action of vecuronium. * **Warfarin:** Piperacillin may decrease the effect of warfarin; monitor INR closely. * **Methotrexate:** Piperacillin may decrease methotrexate clearance; monitor methotrexate levels. ## Monitoring * **Renal function:** Essential, especially in patients with pre-existing renal impairment or those receiving other nephrotoxic agents. * **Liver function tests:** Baseline and periodically. * **Complete blood count:** Monitor for hematologic changes (e.g., thrombocytopenia, neutropenia). * **Signs of hypersensitivity:** Monitor closely during and after administration. * **Signs of C. difficile infection:** Diarrhea, abdominal cramping, fever. * **Clinical response:** Assess for improvement in signs and symptoms of infection. * **INR:** If patient is on warfarin. ## Clinical Pearls * Piperacillin-tazobactam covers many common pathogens, including *Pseudomonas aeruginosa*. * Reconstitute and dilute according to manufacturer's instructions. Administer as a slow intravenous infusion over at least 30 minutes. * Avoid co-administration with other beta-lactam antibiotics due to potential for inactivation. * Higher doses (e.g., 4.5 g every 6 hours) are typically reserved for more severe infections or specific pathogens like *Pseudomonas aeruginosa*. * If a patient develops a rash, assess for potential hypersensitivity or serum sickness. *** **Disclaimer:** This information is intended for clinical use and does not substitute for professional medical advice. Always consult the most current prescribing information and relevant guidelines for complete details, including indications, contraindications, warnings, precautions, adverse reactions, and drug interactions, before making any treatment decisions. Dosing and frequency may vary based on patient-specific factors and institutional protocols.